Originally Aired: March 28, 2023
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Messenger RNA (mRNA) therapies have gained tremendous traction with the approval of mRNA vaccines to prevent COVID-19 infection. However, manufacturing challenges have complicated large-scale mRNA production necessary for the wide applicability of these new therapies. Not only can the incorporation of the required cap analog be inefficient and costly, but in vitro transcription (IVT) using wild-type T7 RNA polymerase generates double-stranded RNA (dsRNA) byproducts that trigger unwanted immunogenic effects and are difficult to remove at large scale.

Join us for this GEN webinar, where scientists from Codexis and Tune Therapeutics will highlight how engineered enzymes overcome common challenges with capping efficiency and dsRNA impurities in IVT manufacturing of mRNA required for vaccines and cell/gene therapeutics.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelists.

codexis logo

Mathew Miller
Mathew Miller, PhD
Principal Scientist, Molecular and Cellular Engineering
Tyler Goodwin
Tyler Goodwin, PhD
Head of Delivery and Nucleic Acid Therapeutics Platform Development
Tune Therapeutics